AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06207734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of CDK4/6 inhibitor Palbociclib
Description: Continuation of CDK4/6 inhibitor Palbociclib
Study NCT06207734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation of CDK4/6 inhibitor Palbociclib
Description: Discontinuation of CDK4/6 inhibitor Palbociclib
Study NCT06207734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of CDK4/6 inhibitor -Palbociclib
Description: Continuation of CDK4/6 inhibitor -Palbociclib
Study NCT06207734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation of CDK4/6 inhibitor -Palbociclib
Description: Discontinuation of CDK4/6 inhibitor -Palbociclib
Study NCT06207734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of CDK4/6 inhibitor Abemaciclib
Description: Continuation of CDK4/6 inhibitor Abemaciclib
Study NCT06207734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation of CDK4/6 inhibitor Abemaciclib
Description: Discontinuation of CDK4/6 inhibitor Abemaciclib
Study NCT06013189 — intervention group
Intervention type: OTHER
Intervention: Gas Flow Adjustment
Description: Decreased gas flow causes PaCO2 to elevate and prevents alkalosis
Study NCT06065891 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PALN resection
Description: Resection of paraaortic lymph nodes in pancreatic cancer
Study NCT06481566 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic ablative body radiotherapy
Description: The residual primary lung lesions after first-line Almonertinib will be delivered stereotactic ablative body radiotherapy.
Study NCT05245188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate milk shakes - Product 1
Description: 11.3 glucose
Study NCT05245188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate milk shakes - Product 2
Description: 8.84 glucose
Study NCT05245188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate milk shakes - Product 3
Description: 4.24 glucose
Study NCT05245188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate milk shakes - Product 4
Description: 4.36 glucose
Study NCT06463054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Skills Group Training
Description: The investigators will employ Dialectical Behavior Therapy Skills Training in order to experimentally manipulate maternal emotion dysregulation, the targeted mechanism.
Study NCT06463054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention
Description: Safety Planning Intervention (SPI) or SPI only for 6 months, such that all mothers with history of suicidal behavior + ER difficulties will receive SPI.
Study NCT04844528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: oral nicotinamide 500 mg twice daily (BID)
Study NCT04844528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo twice daily for first year. Cross over to oral nicotinamide 500 mg twice daily (BID) for year two.
Study NCT06206811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OD-07656
Description: innate immune modulator
Study NCT04969198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination nicotine replacement therapy (Nicotine patch + nicotine mini-lozenge)
Description: Nicotine patch and mini-lozenge dosing will be based off the 2008 Public Health Services (PHS) Clinical Practice Guideline and package insert with adjustments to account for the delayed start 1-week post-TQD. All participants will receive 2mg mini-lozenge due to the superior palatability of the 2mg lozenges. Participants are encouraged to use at least 5 mini-lozenges per day for the full 8 weeks. Participants who report any smoking or nicotine use (e.g., even a cigarette puff, e-cigarette use) in the 3 days before C-NRT distribution will receive 4 weeks of 14mg and 4 weeks of 7mg nicotine patches. Participants who report complete abstinence from smoking and nicotine in the 3 days before C-NRT distribution will receive 8 weeks of 7mg nicotine patches.
Study NCT06020755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 200mg q2w intravenous
Study NCT06020755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actinomycin-D
Description: 1.25mg/m2，2mg max dose, q2w, intravenous
Study NCT05501795 — intervention group
Intervention type: DEVICE
Intervention: WaveLight® FS200 femtosecond laser
Description: Flap creation with the WaveLight® FS200 femtosecond laser
Study NCT05023811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]RIST4271
Description: \[14C\]RIST4271 oral solution
Study NCT06172764 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplements along with behavioral modification
Description: Vitamin D soft gel capsules of 50,000 IU/week for two months followed by a maintenance dosage of 5000 IU/day for one month.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.
Study NCT06172764 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Topical fluoride application and Vitamin D supplements along with behavioral modification
Description: Professional topical 5% sodium fluoride gel application for 5 minutes on the teeth having ICL.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.~Vitamin D soft gel capsules of 50,000 IU/week for two months followed by a maintenance dosage of 5000 IU/day for one month.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.
Study NCT06172764 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Topical fluoride application along with behavioral modification
Description: Professional topical 5% sodium fluoride gel application for 5 minutes on the teeth having ICL.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.
Study NCT05128877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: relaxation techniques
Description: Mitchell's physiological relaxation technique is based on reciprocal inhibition and involves diaphragmatic breathing and a series of ordered isotonic contractions.
Study NCT06449807 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: crossover point intensity exercise
Description: crossover point intensity exercise
Study NCT04754347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer Aided Detection device
Description: The Computer Aided Detection device, Skout, is designed to help endoscopists detect potential colorectal polyps during colonoscopies. The system performs automated real-time analysis on endoscopic video data to identify potential polyps and produces an informational visual aid around the appropriate sections of the video frames on a display monitor.
Study NCT06583551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin
Description: Botulinum toxin, produced by Clostridium botulinum, is a neurotoxin. Presently, there are 7 serotypes (A, B, C1, D, E, F, G). Botulinum neurotoxin A (BoNT-A) is the most frequently used variant in clinical applications.
Study NCT06583551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Dry needling (DN) is a type of acupuncture therapy, that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points (MTrPs) and muscular, and connective tissues.
Study NCT06583551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myorel
Description: Metacarbamol (380mg), paracetamol (300mg)
Study NCT06583551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Manual therapy (MT) entails the use of the hands to apply a force with a therapeutic intent, including techniques such as massage, joint mobilization/manipulation, myofascial release, nerve manipulation, strain/counterstrain, and acupressure.
Study NCT06583421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-week MVPA intervention
Description: The 4-week MVPA intervention engaged in supervised aerobic exercise, resistance training and interesting sport for 60 minutes, 3 days/week (Monday, Wednesday and Friday). As shown in Table S1, participants completed four sessions including preparation module (15 min), training module (30 min), and relaxation module (15 min). Another aerobic module (15 min) was added in each Friday.
Study NCT04768465 — intervention group
Intervention type: DRUG
Intervention: Pyridostigmine, Prednisone, Tacrolimus
Description: Dose of tacrolimus should be initiated based on CYP3A5\*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Prednisone is administrated with an initial dose of 0.25mg/kg/d and started to tamper with the achievement of MMS or the presence of any intolerable side effects. The rate of tampering is considered by the physician, usually no more than 5mg/month. If the participants failed to maintain MMS, dose of prednisone should be increased 5mg/week to 0.25mg/kg/d and maintained until MMS reached again. After MMS sustained for 1 month, prednisone dose would be tapered again with 2.5mg/month. Calcium and potassium supplements and gastric mucosa protectors could be addressed to avoid any adverse effects of prednisone. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
Study NCT04768465 — intervention group
Intervention type: DRUG
Intervention: Pyridostigmine, Tacrolimus
Description: Dose of tacrolimus should be initiated based on CYP3A5\*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
Study NCT05925023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Oral administration, 1-3 mg/d, sirolimus plasma concentration: 4-15 ng/mL
Study NCT05609955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MgSO4
Description: The treatment group who received intravenous magnesium sulfate therapy with 20% magnesium sulfate regimen, 30mg/kg body weight dissolved in 100ml NaCl in 1 hour intravenously
Study NCT05609955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MgSO4
Description: The treatment group who received intravenous magnesium sulfate therapy with 20% magnesium sulfate regimen, 30mg/kg body weight dissolved in 100ml NaCl in 1 hour intravenously
Study NCT04788056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parasternal Subpectoral Plane Block
Description: Nerve block catheter inserted into plane between rib cartilages and pectoralis muscle.
Study NCT04788056 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Parasternal Subpectoral Plane Block
Description: Nerve block catheter inserted into plane between rib cartilages and pectoralis muscle.
Study NCT05769049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REC610
Description: administered as 2 intramuscular (IM) injections in healthy adults aged 40 years and older
Study NCT05769049 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Shingrix
Study NCT05141409 — intervention group
Intervention type: DEVICE
Intervention: Artificial Intelligence
Description: Artificial Intelligence
Study NCT06353763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality learning program
Description: The immersive virtual reality learning programme was developed by the research team and two nurse experts in chronic wounds, who designed the learning content and script and created six pressure ulcer (PU) cases. Based on the standards of the European Pressure Ulcer Advisory Panel (EPUAP), the National Pressure Ulcer Advisory Panel (NPUAP) and the National Group for the Study and Advice on Pressure Ulcers and Chronic Wounds (GNEAUPP), prevention of healthy skin (case one), management of grade I, II, III and IV PUs (cases two to five) and an infected PU (debridement intervention) were developed. For each case, there was a formative version with immediate feedback and an evaluative one. Before starting the training, the students learned how to use the virtual reality glasses, buttons and joystick by playing a game that trained different dexterity movements. The computer assembly IVR application was developed using Unity 3D and the virtual objects were designed in 3Ds Max.
Study NCT04610333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified MBSR programme
Description: 1 hour group session once a week in 10 weeks
Study NCT06550570 — intervention group
Intervention type: BEHAVIORAL
Intervention: QEVA questionnaire
Description: QEVA questionnaire administered at 2 days pospartum (in hospital) and 4 weeks postpartum (phone call). (specific for the study)
Study NCT06285292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMY
Description: Patients in the intervention group (rehabilitation with the EMY medical device) will undergo 2 rehabilitation sessions with a physiotherapist trained in pelviperineology between M0 and M2. The aim of these sessions will be to learn proper perineal contraction and combat the deficits identified during the physiotherapist's assessment. They will have to perform pelvic-perineal re-education exercises with the EMY device on 3 different days a week, for 15 minutes, over a period of 3 months. Then, for a further 3 months, their program can be modified for free, on-demand use (e.g. 2 x 10 minutes per week). After the main criterion at M6, they will be free to modify their rehabilitation program in the application according to their symptoms, and follow their program until the end of the study
Study NCT05596006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASIMOMMY®
Description: ASIMOMMY 500 mg
Study NCT05596006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Domperidon
Description: Domperidone capsule 10 mg
Study NCT05596006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules of placebo 500mg.
Study NCT04867044 — intervention group
Intervention type: OTHER
Intervention: STUDY
Description: One Hundred Fifty woman patients diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
Study NCT06256926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test Product: Curcuvail® 250mg capsule (Curcuma longa Extractcontaining 35% Curcuminoids)
Description: Curcuma longa Extract containing 35% Curcuminoids Dose: One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
Study NCT06256926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: Placebo product Dose:One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
Study NCT05371548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAM mobile application
Description: See description of intervention group
Study NCT06095167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: without concurrent cisplatin chemotherapy
Description: IMRT without concurrent cisplatin chemotherapy
Study NCT06095167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: with concurrent cisplatin chemotherapy
Description: IMRT with concurrent cisplatin chemotherapy
Study NCT05650671 — intervention group
Intervention type: DEVICE
Intervention: instrumented wheelchair
Description: Measurements of pressure, temperature and humidity at the subject/cushion interface
Study NCT04867044 — intervention group
Intervention type: OTHER
Intervention: Control
Description: healthy woman volunteers
Study NCT04975854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy (Virtual Reality)
Description: Virtual reality scenarios consists of increasingly intense exposures to phobic stimuli (e.g., looking over railings from various floor levels) with the support of the therapist. The goal of VRET is sufficient reduction in anxiety to allow the patients to expose themselves to heights in everyday situations.
Study NCT04975854 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Information Session
Description: This includes 20-minute information session about general principles of exposure therapy before the start of the study.
Study NCT04975854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information Session
Description: This includes 20-minute information session about general principles of exposure therapy before the start of the study.
Study NCT05532033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: A device able to delivery high flow oxygen therapy
Study NCT05532033 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Facial mask
Description: standard oxygen therapy
Study NCT05806840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rapid Adaptation to Prevent Drug Use (RAPD)
Description: RAPD will include a novel bundle of implementation strategies to support rapid responses to urgent drug use events. The strategies deployed will be based on the first step of the After Action Review: critical analysis and reflection.
Study NCT05806840 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Implementation
Description: Standard implementation of the Michigan Model for Health (MMH) includes curriculum materials and as-needed technical assistance provided by a school health coordinator.
Study NCT04601571 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CORTRAK Stylet
Description: The stylet is a component of the CORTRAK feeding tube system used to confirm the correct placement of the feeding tube
Study NCT05603325 — intervention group
Intervention type: OTHER
Intervention: Person Centered Practice
Description: Staff will be asked to:~* Complete two surveys on two occasions, once before the intervention sessions and once following the last session. The first survey is views on patient feedback and the other is about the workplace culture and how person-centred it is.~* Attend 6 x 2 hour facilitated workshops which will involve getting ready to work with patient feedback, establishing values and visions for the intervention group, critically reviewing the ways patients are offered the opportunity to give feedback~* Engage in changes in practice (e.g. how staff offer patients the opportunity to provide feedback and the way staff make changes in response to this feedback);~* Attend a final focus group to evaluate the workshop programme.
Study NCT05603325 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Interviews will be used to gather views about how easy or difficult it is to give feedback and how it feels to consider and/or give feedback
Study NCT05322122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Side-to-side anastomosis duodeno-ileostomy diversion procedure
Description: Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions Magnetic Anastomosis System (The MAGNET System) to Achieve Duodeno-Ileostomy Diversion.
Study NCT05493501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumolertinib monotherapy
Description: Administered orally, once daily as two 55-mg tablets for a total dose of 110 mg.
Study NCT05493501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib monotherapy
Description: 80 mg tablet administered orally, once daily
Study NCT05493501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered by IV Infusion per prescribing information. Maybe be continued as maintenance therapy
Study NCT05493501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
Study NCT05493501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
Study NCT05493501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by IV Infusion given over 4 -6 fixed cycles per prescribing information.
Study NCT05493501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Administered by IV Infusion given over 4 fixed cycles per prescribing information.
Study NCT05493501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered by IV Infusion over 4 fixed cycles per prescribing information.
Study NCT05133674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg
Description: i) a self-testing capillary kit, the rhelise™ kit for measuring the concentrations of tamoxifen, 4-hydroxytamoxifen and Z-endoxifen and ii) a patient interactive digital tool (app) mBraze to collect data about symptoms and guide breast cancer patients on adjuvant tamoxifen.